ID   YTS-1
AC   CVCL_6746
SY   YTS1
DR   BTO; BTO_0003554
DR   Wikidata; Q54995582
RX   PubMed=2733301;
RX   PubMed=3573461;
RX   PubMed=29732388;
CC   Population: Japanese.
CC   Doubling time: 20.2-22.5 hours (PubMed=3573461).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   77Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 11
//
RX   PubMed=2733301; DOI=10.5980/jpnjurol1989.80.379;
RA   Kakizaki H.;
RT   "In vitro and in vivo chemosensitivity of the YTS-1 human bladder
RT   carcinoma cell line.";
RL   Nihon Hinyokika Gakkai Zasshi 80:379-386(1989).
//
RX   PubMed=3573461; DOI=10.5980/jpnjurol1928.77.11_1790;
RA   Kakizaki H., Numasawa K., Suzuki K.;
RT   "Establishment of a new cell line (YTS-1) derived from a human urinary
RT   bladder carcinoma and its characteristics.";
RL   Nihon Hinyokika Gakkai Zasshi 77:1790-1795(1986).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//